abstract |
Provided are anti-PD‑1 antibodies, antigen-binding fragments thereof, and medical uses. Specifically, humanized anti-PD-1 antibodies and antigen-binding fragments thereof comprising specific CDR regions, pharmaceutical compositions comprising anti-PD-1 antibodies and antigen-binding fragments thereof, and their use as medicines are provided. In particular, a use of a humanized anti-PD-1 antibody in the preparation of a drug for treating a PD-1-related disease or disorder is provided. |